Loading…
BioNTech SE is projected to rise to $122.82 by 2027, a +32% move from its current price of $93.00. BNTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $91.39 | $93.02 | $94.68 | +0.02% |
| May 30 | $90.74 | $93.04 | $95.40 | +0.05% |
| May 31 | $90.26 | $93.07 | $95.96 | +0.07% |
| Jun 1 | $89.85 | $93.09 | $96.44 | +0.09% |
| Jun 2 | $89.50 | $93.11 | $96.87 | +0.12% |
| Jun 3 | $89.18 | $93.13 | $97.26 | +0.14% |
| Jun 4 | $88.89 | $93.15 | $97.62 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $88.89 | $93.15 | $97.62 | +0.17% |
| Week 2 | $87.33 | $93.31 | $99.70 | +0.33% |
| Week 3 | $86.18 | $93.46 | $101.36 | +0.50% |
| Week 4 | $85.25 | $93.62 | $102.81 | +0.66% |
| Week 5 | $84.45 | $93.77 | $104.12 | +0.83% |
| Week 6 | $83.75 | $93.93 | $105.34 | +1.00% |
| Week 7 | $83.12 | $94.08 | $106.49 | +1.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioNTech SE is a Germany-based healthcare company that, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. It is incorporated in 2008 and is headquartered in Mainz, Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus, and develops oncology drugs across multiple clinical phases, including Phase III programs such as Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; as well as Phase 2/3 programs like BNT113 for human papillomavirus and head and neck squamous cell carcinoma, and Pumitamig for metastatic colorectal and non-small cell lung cancer.
The company also pursues Phase II oncology candidates such as BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, along with Pumitamig for several other cancers. In addition, it develops BNT166 (Phase II for mpox) and infectious-diseases drugs under Phase 1/2, including BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company’s description highlights a broad immunotherapy and oncology-focused pipeline.
BioNTech SE (BNTX) is a healthcare company focused on immunotherapies with a broad oncology portfolio. The stock is currently priced at $92.14 and has a market capitalization of $23.3B, placing it at rank 521 by market cap. The current price and market position set the stage for a multi-year forecast that envisions substantial upside, especially beyond the near term.
The technical picture shows a bearish tilt in the near term, with the stock trading below short- and long-term moving averages and facing key near-term levels.
A major floor 20.8% below — a decisive break under it would weaken the trend.
The nearest floor, 5.6% below — buyers have tended to step in here.
The nearest ceiling, 20.0% above — a clean break opens room to run.
A major ceiling 30.4% above — clearing it would confirm fresh momentum.
Key BNTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $91.74 | Buy | $91.91 | Buy |
| MA 10 | $90.91 | Buy | $92.00 | Buy |
| MA 20 | $93.80 | Sell | $93.45 | Sell |
| MA 50 | $94.64 | Sell | $95.81 | Sell |
| MA 100 | $100.26 | Sell | $97.98 | Sell |
| MA 200 | $101.03 | Sell | $100.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.85 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -17.54 | Neutral |
| Williams %R (14) | -17.76 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -1.20 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 82.24 | Sell |
| TRIX (15) | -0.26 | Sell |
| Awesome (5,34) | -5.43 | Sell |
| Ultimate (7,14,28) | 60.73 | Neutral |
| Momentum (10) | -0.66 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 92.93 | Buy |
| ADX (14) | 18.14 | Neutral |
| ATR (14) | 1.45 | Info |
The current price is $92.14 with a market cap of $23.3B and a rank of 521. Technical sentiment is BEARISH, with RSI 14 at 40. The SMA50 is $94.57 and the SMA200 is $101.22, indicating a softer near-term trend relative to longer-term averages.
Support sits at $87.79 and resistance at $111.60, framing the immediate risk/reward. The 30-day range spans from $81.43 to $104.26, highlighting the current volatility band for BioNTech SE.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $83.89 | $93.00 | $121.50 | 0% | Neutral | |
| $100.34 | $122.82 | $157.37 | +32% | Bullish | |
| $107.13 | $133.53 | $175.56 | +44% | Bullish | |
| $115.83 | $146.56 | $196.71 | +58% | Bullish | |
| $121.80 | $156.17 | $213.31 | +68% | Bullish | |
| $124.84 | $162.00 | $224.72 | +74% | Bullish | |
| $136.65 | $179.31 | $252.24 | +93% | Bullish | |
| $155.27 | $205.87 | $293.30 | +121% | Bullish | |
| $174.66 | $233.88 | $337.15 | +151% | Bullish | |
| $184.87 | $249.87 | $364.18 | +169% | Bullish | |
| $260.64 | $367.38 | $560.95 | +295% | Bullish | |
| $414.34 | $626.23 | $1,024.69 | +573% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $83.89 | $93.00 | $109.26 | +0.00% |
| June 2026 | $82.27 | $95.97 | $114.13 | +3.19% |
| July 2026 | $80.99 | $95.02 | $114.07 | -0.99% |
| August 2026 | $79.85 | $94.11 | $113.80 | -0.96% |
| September 2026 | $81.48 | $96.38 | $117.24 | +2.41% |
| October 2026 | $82.30 | $97.69 | $119.46 | +1.35% |
| November 2026 | $81.27 | $96.75 | $118.88 | -0.96% |
| December 2026 | $82.46 | $98.45 | $121.50 | +1.75% |
Click any year to see its month-by-month BNTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
BioNTech SE's 2026 outlook centres on $93.00, within a $83.89 to $121.50 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BNTX could reach as high as $157.37, with a base case around $122.82 and support toward $100.34 — roughly +32% from $93.00. Momentum favours further upside here.
Expect BNTX to range from $107.13 to $175.56 through 2028. The $133.53 average target implies a +44% move from current prices. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The BNTX price prediction for 2029 points to an average of $146.56 (low $115.83, high $196.71) — a potential gain of +58% on today's $93.00. Momentum favours further upside here.
In 2030, BNTX is projected to trade between $121.80 and $213.31, averaging $156.17 — a potential gain of +68% from today's $93.00. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
BioNTech SE's 2031 outlook centres on $162.00, within a $124.84 to $224.72 range. That is up +4% on the projected 2030 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2032, BNTX could reach as high as $252.24, with a base case around $179.31 and support toward $136.65 — roughly +93% from $93.00. Buyers look set to stay in control over this stretch.
Expect BNTX to range from $155.27 to $293.30 through 2033. The $205.87 average target implies a +121% move from current prices. That is up +15% on the projected 2032 average. Momentum favours further upside here.
The BNTX price prediction for 2034 points to an average of $233.88 (low $174.66, high $337.15) — a potential gain of +151% on today's $93.00. Buyers look set to stay in control over this stretch.
In 2035, BNTX is projected to trade between $184.87 and $364.18, averaging $249.87 — a potential gain of +169% from today's $93.00. That is up +7% on the projected 2034 average. Momentum favours further upside here.
BioNTech SE's 2040 outlook centres on $367.38, within a $260.64 to $560.95 range. That is up +47% on the projected 2035 average. That marks a +295% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BNTX could reach as high as $1,024.69, with a base case around $626.23 and support toward $414.34 — roughly +573% from $93.00. Momentum favours further upside here.
Investing $1,000 in BNTX today (≈ 10.752688 BNTX) could be worth
$6,733.68
+$5,733.68 (+573%) by 2050 · US Dollar
Based on the average projected BNTX price of $626.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNTXwould be worth at today's price.
$1,000 invested in BNTX on May 27, 2025 (≈ 10.147133 BNTX) would be worth
$943.68
-$56.32 (-5.6%) today · 0.94× · US Dollar
Based on a BNTX entry price of $98.55 vs. today's $93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $90.36 | $1,029.22 | +2.9% |
| 1 month ago | $102.06 | $911.23 | -8.9% |
| 3 months ago | $108.8 | $854.78 | -14.5% |
| 6 months ago | $103.15 | $901.6 | -9.8% |
| 1 year ago | $98.55 | $943.68 | -5.6% |
| All time (5.0y) ago | $206.14 | $451.15 | -54.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNTX forecast.
Our base-case forecast reaches $190.00 around 2033.
Implied market cap at $190.00: $48.05B
The multi-year forecast shows a bullish trajectory from 2027 onward, with the avg price rising from $121.60 in 2027 to $613.52 in 2050 and an overall gain in outlook. The 2030 forecast features an avg of $154.04 with a max of $210.45 and a min of $120.12, yielding an ROI of 67.2% in that year. By 2040, the avg reaches $357.75 with a max of $546.32 and a min of $253.79, producing an ROI of 288.3%.
By 2050, the avg is $613.52 with a max of $1,003.97 and a min of $405.88, for an ROI of 565.9%. The trajectory from 2027 onward is consistently bullish, though these figures are estimates and not guarantees. Factors driving the longer-term upside are not specified here, and investment outcomes may vary.
Investors should consider the inherent uncertainty and that actual results can differ from these forecasts.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $154.04 with a min of $120.12 and a max of $210.45, and an ROI of 67.2%. The sentiment is bullish.
The forecast turns bullish from 2027 onward, with rising avg prices and a growing ROI (e.g., 2027 avg $121.60, 2030 avg $154.04, 2040 avg $357.75, 2050 avg $613.52) and a max path up to $1,003.97 by 2050. These are estimates, not guarantees.
Yes. The forecast shows 2030 max $210.45 and 2031 max $220.07, followed by higher maxs: 2032 $248.70, 2033 $288.10, 2034 $329.92, 2035 $358.49, 2040 $546.32, and 2050 $1,003.97.
Current price is $92.14 and market cap is $23.3B. The stock is ranked 521.
Bearish sentiment with RSI 40. The 30-day range is $81.43 to $104.26, with SMA50 at $94.57 and SMA200 at $101.22. Key support is $87.79 and resistance is $111.60.
BioNTech SE Community Discussion
0Share your BioNTech SE price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.